In 2020, Alverstone Drug House Private Limited began its operations, initiating marketing activities across Kerala—from Ernakulam to Trivandrum. From the outset, there was a consistent demand for medicines. The year also brought the unforeseen challenge of the COVID-19 pandemic, which significantly increased the need for critical care medicines. This surge in demand contributed to substantial business growth during the year.

The General Body Meeting for the financial year was successfully conducted with all shareholders, and the Profit & Loss statement was presented and approved. The financial statement for the year 2020–2021 was duly filed with the Registrar of Companies (RoC).

In 2021–2022, Alverstone Drug House expanded its operations from being limited to South Kerala to covering all districts across the state. The company successfully distributed critical care and antibiotic medicines throughout Kerala, marking a significant milestone in our growth.

With increased visibility and trust in the market, we were able to attract new investors and gain more interest in funding our operations. To discuss the roadmap for further business expansion, the Annual General Body Meeting was conducted. Key operational strategies were reviewed, and necessary resolutions were passed.

The financial statement for the year 2021–2022 was presented during the meeting, and the Profit & Loss account for the year was duly filed with the Registrar of Companies (RoC).

In 2022–2023, Alverstone Drug House continued to expand its business, with our products gaining significant traction in the market. As demand grew, particularly from hospitals, we recognized an increased need for a wider product range. In response, we launched a new division, Alverstone Pharma Care, focused on the distribution of tablets. This new division included a total of 43 products across Kerala, further strengthening our position in the pharmaceutical industry.

Building on our success in Kerala, we took our first steps toward global expansion by initiating operations in the UAE. Discussions for this expansion were held, attracting the attention of new investors eager to participate in our growth. This international move also paved the way for further investment in our new projects.

During the 2022–2023 Annual General Body Meeting, it was decided to establish a corporate office in Dubai, marking a key milestone in our global expansion strategy. The financial performance for the fiscal year 2022–2023 was reviewed, and the Profit & Loss statement was submitted to the Registrar of Companies (RoC). All operations showed significant growth, highlighting the company's strong position in the market.

In 2023–2024, Alverstone Drug House took significant steps toward expanding its global presence by establishing a corporate office in Dubai. The Dubai office was inaugurated, marking the beginning of our entry into the cosmetics business. This strategic move opened up new avenues for growth and diversification.

To further strengthen our financial position, we hosted an online investors' meetup, which successfully attracted additional investors, fueling our expansion efforts. The business experienced substantial growth, leading to an improved profit margin in the market.

The financial performance for the fiscal year 2023–2024 was reviewed, and the Profit & Loss statement was filed with the Registrar of Companies (RoC). During the Annual General Body Meeting, it was decided to extend operations into South India, aiming to expand the reach of our products and support further growth.

In 2024–2025, Alverstone Drug House continued to strengthen its presence in South India, expanding operations across Tamil Nadu, Kerala, Andhra Pradesh, Telangana, and Karnataka. The inauguration events in each region were graced by different distinguished guests, including MP Nk Premachandran, Minister Rajeev, award-winning actors, and renowned doctors. Their participation in the launch activities helped create a positive impact on the community and significantly enhanced our brand visibility in each market.

A total of 56 products were marketed across South India, leading to a major shift in our business operations. This expansion contributed to a notable increase in our annual profits, marking a significant milestone in our growth.

In addition to the regional expansion, we made strides toward our dream project, the AIM Plant, which is set to be established at the 360 Science Park. We also successfully launched our head office at the 360 Science Park and began operations there.

The financial performance for the fiscal year 2024–2025 was reviewed, and the Profit & Loss statement was submitted to the Registrar of Companies (RoC). From starting with just 7 expatriate investors, our company has now grown to over 100 shareholders, reflecting the strong growth and confidence in our long-term vision.

In 2025–2026, the Alverstone Group of Companies operated as a unified and strategic force, with each division playing a key role in driving collective growth. Alverstone Drug House continued its focus on medicine marketing, while Alverstone IHDE and Kuly de Paris managed our international operations from Dubai. Alverstone Pharma Care took significant steps toward the development of the AIM manufacturing plant, and Alverstone Medcity led the expansion of our hospital and healthcare services.

To enhance our presence in the healthcare sector, we embarked on establishing a hospital chain under Alverstone Medcity. The first clinic in Kollam is in the process of being set up, with the space agreement already completed. The operational steps are progressing well, and we are confident that this will be a significant addition to our healthcare initiatives.

This integrated approach across the different arms of the Alverstone Group has strengthened our ability to operate efficiently, positioning us for long-term growth and success.